Abstract
Intracerebral hemorrhage (ICH) accounts for 15% of all strokes in the US and Europe and 20% to 30% in Asian populations. ICH is associated with a higher morbidity, disability and mortality than ischemic strokes. Primary ICH originates from spontaneous rupture of small arteries and arterioles previously damaged by chronic hypertension or amyloid angiopathy. Secondary ICH is associated with underlying vascular abnormalities or other pathologies. Manifestation is acute with focal neurological signs and features of raised intracranial pressure. Despite our improved understanding of the pathophysiology of hematoma expansion and edema formation, management is primarily supportive, and outcomes remain poor. A recently published report has confirmed that there is no overall benefit from early surgery when compared with initial conservative treatment. In contrast, treatment with recombinant activated factor VII within 4 hours of onset limits hematoma growth at 24 hours, and reduces mortality and improves functional outcomes at 90 days. Several ICH scoring methods have recently been proposed for better prediction of outcome. These scoring methods may be useful in selecting suitable patients for clinical trials. Microbleeds are commonly seen on magnetic resonance imaging. Further studies are awaited to clarify the association between microbleeds and the future risk of ICH.
Keywords: Activated factor VII, early surgery, intracerebral hemorrhage, microbleeds, outcome, stroke assessment
Reviews on Recent Clinical Trials
Title: Update on Medical and Surgical Management of Intracerebral Hemorrhage
Volume: 2 Issue: 3
Author(s): Raymond Tak Fai Cheung
Affiliation:
Keywords: Activated factor VII, early surgery, intracerebral hemorrhage, microbleeds, outcome, stroke assessment
Abstract: Intracerebral hemorrhage (ICH) accounts for 15% of all strokes in the US and Europe and 20% to 30% in Asian populations. ICH is associated with a higher morbidity, disability and mortality than ischemic strokes. Primary ICH originates from spontaneous rupture of small arteries and arterioles previously damaged by chronic hypertension or amyloid angiopathy. Secondary ICH is associated with underlying vascular abnormalities or other pathologies. Manifestation is acute with focal neurological signs and features of raised intracranial pressure. Despite our improved understanding of the pathophysiology of hematoma expansion and edema formation, management is primarily supportive, and outcomes remain poor. A recently published report has confirmed that there is no overall benefit from early surgery when compared with initial conservative treatment. In contrast, treatment with recombinant activated factor VII within 4 hours of onset limits hematoma growth at 24 hours, and reduces mortality and improves functional outcomes at 90 days. Several ICH scoring methods have recently been proposed for better prediction of outcome. These scoring methods may be useful in selecting suitable patients for clinical trials. Microbleeds are commonly seen on magnetic resonance imaging. Further studies are awaited to clarify the association between microbleeds and the future risk of ICH.
Export Options
About this article
Cite this article as:
Tak Fai Cheung Raymond, Update on Medical and Surgical Management of Intracerebral Hemorrhage, Reviews on Recent Clinical Trials 2007; 2 (3) . https://dx.doi.org/10.2174/157488707781662751
DOI https://dx.doi.org/10.2174/157488707781662751 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Variation of Antioxidant Capacity in Different Layers of Onion (Allium cepa L.) At Two Different Stages of Maturation
Current Nutrition & Food Science Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Gut Microbiota: A New Marker of Cardiovascular Disease
Current Pharmaceutical Design Radiolabelling of Ascorbic Acid: A New Clue to Clarify its Action as an Anticancer Agent?
Current Radiopharmaceuticals Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia
Current Alzheimer Research Combination of Fenofibrate with Non-Statin Drug Regimens
Current Pharmaceutical Design Pharmacogenomic Approaches for Tailored Anti-Leukemic Therapy in Children
Current Medicinal Chemistry Food Applications for Flaxseed and its Components: Products and Processing
Recent Patents on Food, Nutrition & Agriculture Comparison of Clinical Outcomes Following Single versus Multivessel Percutaneous Coronary Intervention Using Biodegradable Polymer Coated Sirolimus-Eluting Stent in an All-comers Patient Population
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Significance of the Cardio-Ankle Vascular Index (CAVI) in Hypertension
Current Hypertension Reviews Decentralization and Virtualization of INR-based Anticoagulation Control During the COVID-19 Pandemic
Cardiovascular & Hematological Disorders-Drug Targets Insulin Resistance and Alzheimers Disease Pathogenesis: Potential Mechanisms and Implications for Treatment
Current Alzheimer Research Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome
Current Bioactive Compounds Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage)
Current Pharmaceutical Design Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design Preclinical Pharmacokinetics: An Approach Towards Safer and Efficacious Drugs
Current Drug Metabolism Regional Cerebral Blood Flow and Cerebrovascular Reactivity in Alzheimer’s Disease and Vascular Dementia Assessed by Arterial Spinlabeling Magnetic Resonance Imaging
Current Neurovascular Research Stage A: Can Heart Failure Be Prevented?
Current Cardiology Reviews The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design